The Affordable Care Act, which led to the creation of state and federally run health insurance exchanges that launched last week, is generally thought of as being for the uninsured. But that's not entirely true. It could help the Callaways, too.
The law offers many new protections for anyone who has employer-provided health insurance. It could even help some people with hard-to-afford plans and/or plans that don't cover enough of their health costs.
INTERACTIVE: What does this mean for you?
Hot Asian Stocks To Own Right Now: ING US Inc (VOYA)
ING U.S., Inc., incorporated on April 7, 1999, is a retirement, investment and insurance company serving the financial needs of approximately 13 million individual and institutional customers in the United States. The Company offers its products and services through a group of financial intermediaries, independent producers, affiliated advisors and dedicated sales specialists throughout the United States. The Company operates its principal businesses through three business lines: Retirement Solutions, Investment Management and Insurance Solutions. In addition, it also has closed Blocks and corporate reporting segments. Closed Blocks consists of three businesses where it has placed its portfolios in run-off-Closed Block Variable Annuity, Closed Block Institutional Spread Products and Closed Block Other. The Company�� corporate segment includes its corporate activities and corporate-level assets and financial obligations.
Retirement Solutions
The Company is a provider of retirement services and products in the United States. The Company provides a product range addressing both the accumulation and income distribution needs of customers, through a distribution footprint of nearly 2,500 affiliated representatives and thousands of non-affiliated agents and third party administrators (TPAs). The Company�� Retirement Solutions business consists of two financial segments: Retirement and Annuities.
Retirement provides tax-deferred, employer-sponsored retirement savings plans and administrative services to more than 49,000 plan sponsors covering approximately 5.3 million plan participants in corporate, education, healthcare and government markets. Retirement also provides rollover IRAs, and other retail financial products as well as comprehensive financial advisory services to individual customers. Annuities provide fixed and indexed annuities, tax-qualified mutual fund custodial products and payout annuities for pre-retirement wealth accumulation and post-retirement i! ncome management sold through multiple channels.
Investment Management
The Company is a service asset manager delivering client-oriented investment solutions and advisory services. The Company serves both individual and institutional customers, offering them domestic and international fixed income, equity, multi-asset and alternative investment products and solutions across a range of geographies, investment styles and capitalization spectrums.
Insurance Solutions
The Company is a provider of life insurance in the United States. The Company�� Insurance Solutions business consists of two financial segments: Individual Life and Employee Benefits. Individual Life provides wealth protection and transfer opportunities through universal, variable, and term products, distributed through independent channels to meet the needs of a range of customers from the middle-market through affluent market segments. Employee Benefits provides stop loss, group life, voluntary employee-paid and disability products to mid-sized and large businesses.
Closed Blocks
The Company separated its Closed Block Variable Annuity and Closed Block Institutional Spread Products segments from its other operations, placing them in run-off, and made a strategic decision to stop actively writing new retail variable annuity products with substantial guarantee features and to run-off the institutional spread products portfolio over time. The Company�� focus in managing its Closed Block Variable Annuity segment is on protecting regulatory reserves.
The Company competes with Fidelity, Vanguard, Morgan Stanley Smith Barney, Bank of America Merrill Lynch, TIAA-CREF and Ameriprise.
Advisors' Opinion:- [By Jay Jenkins]
In the video below, Motley Fool contributor Jay Jenkins highlights three banks that are ahead of the curve:�Citigroup (NYSE: C ) , Bank of America (NYSE: BAC ) , and Capital One's (NYSE: COF ) 360 product (originally developed by ING U.S. (NYSE: VOYA ) ).
- [By Jessica Alling]
The life and retirement segments at Genworth Financial (NYSE: GNW ) , Hartford Finanical (NYSE: HIG ) , and ING (NYSE: VOYA ) were among 11 insurers slapped with a new settlement for unpaid benefits. In the video below, Motley Fool contributor Jessica Alling discusses how the insurers misconduct lead to unpaid monies, how much the settlement is, and how investors should be looking at the situation.
- [By Mike Deane]
On Friday, Dutch company ING Groep announced that it will be selling off shares in the American arm of its firm, ING US Inc (VOYA).
VOYA went public in May of this year, and its Dutch parent company currently holds a stake in 71% of the company. ING US will rebrand as Voya Financial, according to the Associated Press. ING Groerp did not disclose the timing or size of the sale.
VOYA shares were down 48 cents, or 1.62%, at market close on Monday. YTD the company’s stock is up over 44%.
Best Cheapest Companies To Watch In Right Now: LDK Solar Co. Ltd.(LDK)
LDK Solar Co., Ltd., together with its subsidiaries, engages in the design, development, manufacture, and marketing of photovoltaic (PV) products; and development of power plant projects. It offers solar-grade and semiconductor-grade polysilicon; and multicrystalline and monocrystalline solar wafers to the manufacturers of solar cells and solar modules. The company also provides wafer processing services to monocrystalline and multicrystalline solar cell and module manufacturers; and sells silicon materials, such as ingots and polysilicon scraps. In addition, it engages in the production and sale of solar cells and modules to developers, distributors, and system integrators; and design and development of solar power projects in Europe, the United States, and China, as well as provides engineering, procurement, and construction services. LDK Solar Co., Ltd. operates in Europe, the Asia Pacific, and North America. The company was founded in 2005 and is based in Xinyu City, t he People?s Republic of China.
Advisors' Opinion:- [By Paul Ausick]
Notable earnings reports currently on tap for next week: Qihu 360 Technology Co. Ltd. (NASDAQ: QIHU), Avago Technologies Ltd. (NASDAQ: AVGO), LDK Solar Co. Ltd. (NYSE: LDK), Tiffany & Co. (NYSE: TIF), Joy Global Inc. (NYSE: JOY), Campbell Soup Co. (NYSE: CPB), JA Solar Holdings Co. Ltd. (NASDAQ: JASO), Krispy Kreme Doughnuts Inc. (NYSE: KKD), and ReneSola Ltd. (NYSE: SOL).
Best Cheapest Companies To Watch In Right Now: China BAK Battery Inc.(CBAK)
China BAK Battery, Inc., together with its subsidiaries, engages in the manufacture, commercialization, and distribution of various standard and customized lithium ion rechargeable batteries. The company offers various products, including aluminum-case prismatic, cylindrical, lithium polymer, and high-power lithium battery cells. Its battery cells are the principal component of rechargeable batteries used to power cellular phones and smart phones; notebook computers, tablet computers, and e-book readers; portable consumer electronics, such as digital cameras, portable media players, portable gaming devices, personal digital assistants, camcorders, and Bluetooth headsets; and electric bicycles, light electric vehicles, hybrid electric vehicles, cordless power tools, and uninterruptible power supplies. The company serves battery pack manufacturers, original equipment manufactures, and replacement battery manufacturers primarily in the People?s Republic of China, Taiwan, Hon g Kong, India, the United States, the Middle East, Italy, Germany, and Turkey. China BAK Battery, Inc. was founded in 2001 and is based in Shenzhen, China.
Advisors' Opinion:- [By Ant贸nio Costa] China BAK Battery Inc. (NASDAQ: CBAK) still looks pretty good on the technical daily chart with volume expanding as it moves higher, MACD crossover too. CBAK continues to look bullish and had a decent day Friday. ( click to enlarge )
- [By Bryan Murphy]
It's fun to be right, but there's such a thing as being a little too right, too fast. Such is the case with China BAK Battery Inc. (NASDAQ:CBAK) ... a stock yours truly was touting as a buy-worthy ticker just two days ago following news from Tesla Motors (NASDAQ:TSLA) that it was getting into the battery-pack business so it could become its own supplier for its electric vehicle business (Tesla automobiles need a huge battery pack to run). If there was enough demand for a carmaker to get into the game, then surely it meant there was enough potential business for an established battery market to bear plenty of fruit for CBAK too.
Best Cheapest Companies To Watch In Right Now: Clovis Oncology Inc (CLVS)
Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.
CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine
CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.
CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor
CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.
The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.
CO-338-a PARP Inhibitor
CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!
The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.
Advisors' Opinion:- [By John Udovich]
Biotech stocks and especially anything related to cancer has been a hot sector this year with plenty of good news with small cap cancer stocks like Clovis Oncology Inc (NASDAQ: CLVS), Celldex Therapeutics, Inc.(NASDAQ: CLDX) and MetaStat Inc (OTCBB: MTST). also recently reporting their share of good news. I should point out that one reason biotech or rather cancer is a hot area right now is because�big pharma companies who are loosing their�patent protection are looking for acquisitions with cancer in particular being a hot area. In addition and�thanks to a series of breakthroughs that have helped researchers understand the genetic basis of the disease, more investment or R&D dollars are flowing into cancer therapies or small cap biotechs in the cancer space.�With that in mind, here is the latest news about cancer or the cancer stocks or drug companies involved with finding new cancer treatments:
- [By Lauren Pollock]
Biotech company Clovis Oncology Inc.(CLVS), which was considering a sale, didn’t enter any deal talks and is no longer seeking bids, Bloomberg News reported, citing a person with knowledge of the matter. Shares dropped 14% to $63.51 premarket.
- [By Jake L'Ecuyer]
Clovis Oncology (NASDAQ: CLVS) was also up, gaining 7.26 percent to $79.35 after the company announced 2014 objectives and financial outlook. The company projected to initiate three global registration studies for CO-1686.
- [By Sean Williams]
Clovis Oncology (NASDAQ: CLVS )
Welcome to fantasyland; population: Clovis shareholders! As my Foolish colleague and health care analyst David Williamson pointed out this week, shareholders enjoyed the best possible perk of biotech ownership Monday based on ASCO data -- a daily double. Clovis shares exploded higher as both its Rucaparib study of solid tumors, and CO-1686 for EGFR-mutant non-small-cell lung cancer, demonstrated strong early-stage results.
Best Cheapest Companies To Watch In Right Now: Dr. Reddy's Laboratories Ltd(RDY)
Dr. Reddy?s Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec Internatio nal for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddy?s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.
Advisors' Opinion:- [By Seth Jayson]
Dr. Reddy's Laboratories (NYSE: RDY ) reported earnings on May 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q4), Dr. Reddy's Laboratories beat expectations on revenues and beat expectations on earnings per share. - [By Benjamin Shepherd] We’re now into day 15 of the US government shutdown, as House Republicans stubbornly try to defund Obamacare. No matter what sort of deal is eventually struck, health care costs aren’t likely to come down any time soon. And that’s good news for generic drug makers.
Dr. Reddy’s Laboratories (NYSE: RDY) is one of the biggest players in generic drugs, offering more than 200 off-brand medications in the areas of cardiovascular disease, pain management and oncology, among others. In fact, this India-based company has become one of the largest makers of generics in the world, helping to drive more than 20 percent annual compounded earnings growth at the company over the past decade. - [By Ben Levisohn]
Teva has dropped 7.7% to $37.85 today at 3:23 p.m. but doesn’t seem to be spreading though the generic drug space. Taro Pharmaceuticals (TARO) ha gained 1.1% to $79, while Actavis (ACT) has gained 1.2% to $156.25 and Dr. Reddy’s Laboratories (RDY) has advanced 1% to $40.24. Mylan (MYL) has dropped 0.7% to $38.40.
Best Cheapest Companies To Watch In Right Now: Apple Inc.(AAPL)
Apple Inc., together with subsidiaries, designs, manufactures, and markets personal computers, mobile communication and media devices, and portable digital music players, as well as sells related software, services, peripherals, networking solutions, and third-party digital content and applications worldwide. The company sells its products worldwide through its online stores, retail stores, direct sales force, third-party wholesalers, resellers, and value-added resellers. In addition, it sells third-party Mac, iPhone, iPad, and iPod compatible products, including application software, printers, storage devices, speakers, headphones, and other accessories and peripherals through its online and retail stores; and digital content and applications through the iTunes Store. The company sells its products to consumer, small and mid-sized business, education, enterprise, government, and creative markets. As of September 25, 2010, it had 317 retail stores, including 233 stores in the United States and 84 stores internationally. The company, formerly known as Apple Computer, Inc., was founded in 1976 and is headquartered in Cupertino, California.
Advisors' Opinion:- [By Wallace Witkowski]
Apple Inc. (AAPL) �is telling shareholders to reject a share buyback plan being pitched by billionaire investor Carl Icahn, according to a Securities and Exchange Commission filing late Friday.
No comments:
Post a Comment